Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Sells $269,400.00 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Kevin Lee sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, October 11th. The stock was sold at an average price of $53.88, for a total value of $269,400.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Kevin Lee also recently made the following trade(s):

  • On Friday, August 27th, Kevin Lee sold 1,808 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $36.02, for a total value of $65,124.16.
  • On Tuesday, August 31st, Kevin Lee sold 11,225 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $36.33, for a total value of $407,804.25.
  • On Monday, July 26th, Kevin Lee sold 100 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $36.00, for a total value of $3,600.00.
  • On Friday, July 23rd, Kevin Lee sold 4,782 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $36.02, for a total value of $172,247.64.
  • On Friday, July 16th, Kevin Lee sold 609 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $34.00, for a total value of $20,706.00.

Shares of NASDAQ:BCYC opened at $56.38 on Thursday. The company has a market capitalization of $1.44 billion, a PE ratio of -19.99 and a beta of -0.42. The company has a debt-to-equity ratio of 0.21, a current ratio of 9.36 and a quick ratio of 9.36. The business has a fifty day moving average price of $38.74 and a two-hundred day moving average price of $33.55. Bicycle Therapeutics plc has a 1 year low of $17.68 and a 1 year high of $56.81.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, August 5th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.03). The firm had revenue of $1.79 million for the quarter, compared to the consensus estimate of $2.51 million. Bicycle Therapeutics had a negative return on equity of 50.43% and a negative net margin of 546.62%. Sell-side analysts anticipate that Bicycle Therapeutics plc will post -2.82 earnings per share for the current year.

BCYC has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $65.00 price target (up from $39.00) on shares of Bicycle Therapeutics in a research report on Friday, October 8th. Roth Capital increased their price target on Bicycle Therapeutics from $35.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, October 7th. B. Riley increased their price target on Bicycle Therapeutics from $56.00 to $72.00 and gave the company a “buy” rating in a research report on Friday, October 8th. Piper Sandler increased their price target on Bicycle Therapeutics from $46.00 to $76.00 and gave the company an “overweight” rating in a research report on Friday, October 8th. Finally, JMP Securities restated a “buy” rating and issued a $53.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, August 11th. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Bicycle Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $63.67.

Hedge funds have recently bought and sold shares of the company. WealthShield Partners LLC bought a new position in shares of Bicycle Therapeutics during the 2nd quarter worth $27,000. Citigroup Inc. grew its stake in shares of Bicycle Therapeutics by 107.8% during the 2nd quarter. Citigroup Inc. now owns 1,066 shares of the company’s stock worth $32,000 after acquiring an additional 553 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Bicycle Therapeutics during the 1st quarter worth $39,000. Personal CFO Solutions LLC bought a new position in shares of Bicycle Therapeutics during the 2nd quarter worth $221,000. Finally, Geode Capital Management LLC bought a new position in shares of Bicycle Therapeutics during the 2nd quarter worth $227,000. Institutional investors own 48.67% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles.

Featured Story: Federal Reserve

Insider Buying and Selling by Quarter for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.